Daiichi Sankyo Gains Marketing Rights To Ajinomoto's Diabetes Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase I compound AJD101 has a new mechanism of action that stimulates insulin independent glucose uptake in preclinical studies, according to the two Tokyo-based drug makers.
You may also be interested in...
Japanese Mergers Provide Opening For Biotech Deals - Novartis Licensing Head
Recent mergers in the Japanese pharmaceutical market have provided U.S. and European biotechs enhanced opportunities to partner with Japanese pharmas looking to fill pipelines and compete globally, according to Novartis Global Head of Business Development and Licensing Anthony Rosenberg. However, Rosenberg cautioned that this same dynamic also could mean fewer opportunities for multinational pharmas to license compounds from their Japanese counterparts
Japanese Mergers Provide Opening For Biotech Deals – Novartis Licensing Head
But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.
Japanese Mergers Provide Opening For Biotech Deals – Novartis Licensing Head
But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: